Page 7 - Nasdaq Cbay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Golden State Equity Partners purchased a new position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 50,000 shares of the biopharmaceutical company’s stock, valued at approximately $436,000. A number of other hedge funds have […]

NEWARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on...

CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective increased by Raymond James from $17.00 to $33.00 in a research report report published on Thursday morning, Marketbeat.com reports. The brokerage currently has a strong-buy rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. BTIG Research increased their […]

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report)’s share price traded up 7.9% during trading on Monday after BTIG Research raised their price target on the stock from $22.00 to $24.00. BTIG Research currently has a buy rating on the stock. CymaBay Therapeutics traded as high as $17.55 and last traded at $17.53. 938,534 shares […]

Affinity Asset Advisors LLC trimmed its position in shares of CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Free Report) by 5.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,083,118 shares of the biopharmaceutical company’s stock after selling 60,413 shares during the quarter. CymaBay Therapeutics […]